These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12537259)

  • 1. Prescribing outside the limits of marketing authorizations and reimbursement by the French universal health insurance system.
    Avouac B
    Joint Bone Spine; 2002 Dec; 69(6):534-7. PubMed ID: 12537259
    [No Abstract]   [Full Text] [Related]  

  • 2. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
    Schmidt K
    MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
    [No Abstract]   [Full Text] [Related]  

  • 3. [Limited prescribing freedom by federal cost regulation?].
    Lasek R
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient access to pharmaceuticals: an international comparison.
    Cohen J; Faden L; Predaris S; Young B
    Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
    Yang BM; Bae EY; Kim J
    Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug prescriptions outside the marketing product license and its responsibilities].
    Gromb S; Maurain C; Carbonnel S
    Presse Med; 2000 May 27-Jun 3; 29(19):1053-7. PubMed ID: 10874916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
    Thatte U; Hussain S; de Rosas-Valera M; Malik MA
    Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Limiting prescribing freedom in the hospital].
    Jansen C
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):635-7; discussion 638. PubMed ID: 9527459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes to the Pharmaceutical Benefits Advisory Committee.
    Henry DA; Birkett DJ
    Med J Aust; 2001 Mar; 174(5):209-10. PubMed ID: 11280687
    [No Abstract]   [Full Text] [Related]  

  • 10. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
    Thöns M
    MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
    [No Abstract]   [Full Text] [Related]  

  • 11. [How AMOG limits the supply of diabetes drugs].
    Oberhofer E
    MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulation of health-related technologies in Germany.
    Perleth M; Busse R; Schwartz FW
    Health Policy; 1999 Jan; 46(2):105-26. PubMed ID: 10346284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Employment of unlicensed assistants has expensive consequences].
    Steinbrück R
    Klin Monbl Augenheilkd; 2015 May; 232(5):632. PubMed ID: 26199961
    [No Abstract]   [Full Text] [Related]  

  • 14. [Barmer reimbursement insurance pays pharmacists a fee for monitoring physicians. Pharmacists now control their prescriptions!].
    Schmidt K
    MMW Fortschr Med; 2004 May; 146(21):55-6. PubMed ID: 15373087
    [No Abstract]   [Full Text] [Related]  

  • 15. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.
    Bae EY; Lee EK
    Value Health; 2009; 12 Suppl 3():S36-41. PubMed ID: 20586979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare.
    Shah J
    Nat Biotechnol; 2003 Jul; 21(7):747-53. PubMed ID: 12833092
    [No Abstract]   [Full Text] [Related]  

  • 20. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
    Dalton A
    Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.